Eleonora Cremonini
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Eleonora Cremonini has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
Alessia Ortombina
A Department of Diagnostics and Public Health , University of Verona , Verona , Italy
1 shared publication- Angela Sandri
General and Upper GI Surgery, Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy
1 shared publication - Claudio Sorio
Cystic Fibrosis Laboratory “D. Lissandrini”, Department of Medicine, Division of General Pathology, University of Verona, 37134 Verona, Italy
1 shared publication Federico Boschi
B Department of Computer Science , University of Verona , Verona , Italy
1 shared publicationGabriella Bergamini
C Department of Medicine , University of Verona , Verona , Italy
1 shared publication- Maria del Mar Lleò
Diagnostic and Public Health Department, University of Verona, 37134 Verona, Italy
1 shared publication
Latest Publications
- Open Access
- 27 July 2018
- Published by Taylor & Francis in Virulence
- Vol. 9 (1) , 1008-1018
Inhibition of Pseudomonas aeruginosa secreted virulence factors reduces lung inflammation in CF mice
Background: Cystic fibrosis (CF) lung infection is a complex condition where opportunistic pathogens and defective immune system cooperate in developing a constant cycle of infection and inflammation. The major pathogen, Pseudomonas aeruginosa, secretes a multitude of virulence factors involved in host immune response and lung tissue damage. In this study, we examined the possible anti-inflammatory effects of molecules inhibiting P. aeruginosa virulence factors. Methods: Pyocyanin, pyoverdine and proteases were measured in bacterial culture supernatant from different P. aeruginosa strains. Inhibition of virulence factors by sub-inhibitory concentrations of clarithromycin and by protease inhibitors was evaluated. Lung inflammatory response was monitored by in vivo bioluminescence imaging in wild-type and CFTR-knockout mice expressing a luciferase gene under the control of a bovine IL-8 promoter. Results: The amount of proteases, pyocyanin and pyoverdine secreted by P. aeruginosa strains was reduced after growth in the presence of a sub-inhibitory dose of clarithromycin. Intratracheal challenge with culture supernatant containing bacteria-released products induced a strong IL-8-mediated response in mouse lungs while lack of virulence factors corresponded to a reduction in bioluminescence emission. Particularly, sole inactivation of proteases by inhibitors Ilomastat and Marimastat also resulted in decreased lung inflammation. Conclusions: Our data support the assumption that virulence factors are involved in P. aeruginosa pro-inflammatory action in CF lungs; particularly, proteases seem to play an important role. Inhibition of virulence factors production and activity resulted in decreased lung inflammation; thus, clarithromycin and protease inhibitors potentially represent additional therapeutic therapies for P. aeruginosa-infected patients.
- 27 July 2018
- Published by Taylor & Francis in Virulence
- Vol. 9 (1) , 1008-1018
Open AccessInhibition of Pseudomonas aeruginosa secreted virulence factors reduces lung inflammation in CF mice
Background: Cystic fibrosis (CF) lung infection is a complex condition where opportunistic pathogens and defective immune system cooperate in developing a constant cycle of infection and inflammation. The major pathogen, Pseudomonas aeruginosa, secretes a multitude of virulence factors involved in host immune response and lung tissue damage. In this study, we examined the possible anti-inflammatory effects of molecules inhibiting P. aeruginosa virulence factors. Methods: Pyocyanin, pyoverdine and proteases were measured in bacterial culture supernatant from different P. aeruginosa strains. Inhibition of virulence factors by sub-inhibitory concentrations of clarithromycin and by protease inhibitors was evaluated. Lung inflammatory response was monitored by in vivo bioluminescence imaging in wild-type and CFTR-knockout mice expressing a luciferase gene under the control of a bovine IL-8 promoter. Results: The amount of proteases, pyocyanin and pyoverdine secreted by P. aeruginosa strains was reduced after growth in the presence of a sub-inhibitory dose of clarithromycin. Intratracheal challenge with culture supernatant containing bacteria-released products induced a strong IL-8-mediated response in mouse lungs while lack of virulence factors corresponded to a reduction in bioluminescence emission. Particularly, sole inactivation of proteases by inhibitors Ilomastat and Marimastat also resulted in decreased lung inflammation. Conclusions: Our data support the assumption that virulence factors are involved in P. aeruginosa pro-inflammatory action in CF lungs; particularly, proteases seem to play an important role. Inhibition of virulence factors production and activity resulted in decreased lung inflammation; thus, clarithromycin and protease inhibitors potentially represent additional therapeutic therapies for P. aeruginosa-infected patients.